clinical trial · NCT00418821
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
Genzyme, a Sanofi Company·phase4·terminated·n = 2
Mucopolysaccharidosis IHurler's SyndromeHurler-Scheie SyndromeScheieLaronidase
brief summary
The purpose of this study is to determine if laronidase is present in the breast milk of post-partum women receiving Aldurazyme® (laronidase) and the effects of Aldurazyme (laronidase) on the growth, development, and immunologic response of their breastfed infants.
started
Oct 22, 2010
primary completion
Dec 21, 2022
completion
Dec 21, 2022
last updated
Feb 20, 2024
detailed description
Recruitment is not limited to the facility listed; facilities not yet active may be added upon identification of a patient.
official title
A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme® (Laronidase) Treatment on Lactation in Women With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol